Sensus Healthcare, a Boca Raton Fla. medical device maker, has been cleared by CFDA to expand its operations in China, bringing its skin-treatment technology to a country with more than 1.4 billion people.
Specifically, we are talking about Sensus Healthcare’s SRT-100. A device that non-invasively treats skin conditions. i.e.keloids, a type of benign fibrous tissue formed at the area of scars/trauma.
Scientists have found that keloids appear most frequently among those of African, Latin and Asian descent. Since China relaxed its one-child policy, the incidence of keloids has increased due to the prevalence of Cesarean section births. This delivery procedure causes scarring.
Sensus will partner with Chindex Medical Limited. A wholly owned subsidiary of Shanghai-based Fosun Pharma International. The device has been sold in China for treatment of non-melanoma skin cancer.
“CFDA clearance of the SRT-100 for the treatment and prevention of keloids is an important milestone for Sensus, and a step forward for healthcare in China, especially women’s health,” said Sensus CEO Joe Sardano.
About China Med Device, LLC (CMD) CMD provides turn-key solution for Western medtech companies with regulatory and commercialization services. CMD helps its clients accelerate China entry and growth by offering: market Intelligence and research; CFDA regulatory services (premarket submission, clinical evaluation, clinical trial design & management, post market compliance and legal representation), and other commercial services. If you have an inquiry or feedback regarding our services please email us at info@ChinaMedDevice.com.